Cover Image
市場調查報告書

Prexton Therapeutics SA 產品平台分析

Prexton Therapeutics SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319991
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Prexton Therapeutics SA 產品平台分析 Prexton Therapeutics SA - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 20 Pages
簡介

Prexton Therapeutics SA是總公司在瑞士的醫藥品開發企業,開發帕金森氏症和其他腦部疾病的創新治療藥。該公司著重於透過mGluR4(代謝型麩胺酸受體4)新化合物的設計,利用mGluR4及mGluR3搬運藥物,開發改善帕金森氏症的症狀為目標的新化學物質。

本報告提供Prexton Therapeutics SA 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Prexton Therapeutics SA 基本資料

  • Prexton Therapeutics SA 概要
  • 主要資訊
  • 企業資料

Prexton Therapeutics SA :R&D概要

  • 主要的治療範圍

Prexton Therapeutics SA :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Prexton Therapeutics SA :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Prexton Therapeutics SA :藥物簡介

  • mGluR4 PAMs Lead Series
  • Small Molecules To Agonize mGluR3 For Parkinson Disease
  • Small Molecules to Agonize mGluR4 for Parkinson Disease

Prexton Therapeutics SA :開發平台分析

  • 各標靶
  • 各分子類型
  • 各作用機制

Prexton Therapeutics SA :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07731CDB

Summary

Global Markets Direct's, 'Prexton Therapeutics SA - Product Pipeline Review - 2015', provides an overview of the Prexton Therapeutics SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Prexton Therapeutics SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Prexton Therapeutics SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Prexton Therapeutics SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Prexton Therapeutics SA's pipeline products

Reasons to buy

  • Evaluate Prexton Therapeutics SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Prexton Therapeutics SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Prexton Therapeutics SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Prexton Therapeutics SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Prexton Therapeutics SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Prexton Therapeutics SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Prexton Therapeutics SA Snapshot
    • Prexton Therapeutics SA Overview
    • Key Information
    • Key Facts
  • Prexton Therapeutics SA - Research and Development Overview
    • Key Therapeutic Areas
  • Prexton Therapeutics SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Prexton Therapeutics SA - Pipeline Products Glance
    • Prexton Therapeutics SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Prexton Therapeutics SA - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Prexton Therapeutics SA - Drug Profiles
    • PXT-2331
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize mGluR3 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize mGluR4 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Prexton Therapeutics SA - Pipeline Analysis
  • Prexton Therapeutics SA - Pipeline Products by Target
  • Prexton Therapeutics SA - Pipeline Products by Molecule Type
  • Prexton Therapeutics SA - Pipeline Products by Mechanism of Action
  • Prexton Therapeutics SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Prexton Therapeutics SA, Key Information
  • Prexton Therapeutics SA, Key Facts
  • Prexton Therapeutics SA - Pipeline by Indication, 2015
  • Prexton Therapeutics SA - Pipeline by Stage of Development, 2015
  • Prexton Therapeutics SA - Monotherapy Products in Pipeline, 2015
  • Prexton Therapeutics SA - Preclinical, 2015
  • Prexton Therapeutics SA - Discovery, 2015
  • Prexton Therapeutics SA - Unknown, 2015
  • Prexton Therapeutics SA - Pipeline by Target, 2015
  • Prexton Therapeutics SA - Pipeline by Molecule Type, 2015
  • Prexton Therapeutics SA - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Prexton Therapeutics SA - Pipeline by Stage of Development, 2015
  • Prexton Therapeutics SA - Monotherapy Products in Pipeline, 2015
  • Prexton Therapeutics SA - Pipeline by Top 10 Target, 2015
  • Prexton Therapeutics SA - Pipeline by Top 10 Molecule Type, 2015
  • Prexton Therapeutics SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top